NCT02865811View on ClinicalTrials.gov

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2016

Primary Completion Date

August 31, 2020

Study Completion Date

March 31, 2022

Conditions

Ovarian CancerFallopian Tube CancerPeritoneal Cancer

Interventions

DRUG

Pembrolizumab

"Please see Arms for description."

DRUG

Pegylated Liposomal Doxorubicin (PLD)

"Please see Arms for description."

Trial Locations (3)

11042

Northwell Hospital Monter Cancer Center, Lake Success

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02865811 - Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | Biotech Hunter | Biotech Hunter